Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBITDA (2016 - 2025)

Amphastar Pharmaceuticals has reported EBITDA over the past 13 years, most recently at -$78.8 million for Q4 2025.

  • Quarterly results put EBITDA at -$78.8 million for Q4 2025, down 274.63% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (down 87.36% YoY), and the annual figure for FY2025 was $26.0 million, down 87.36%.
  • EBITDA for Q4 2025 was -$78.8 million at Amphastar Pharmaceuticals, down from $25.3 million in the prior quarter.
  • Over the last five years, EBITDA for AMPH hit a ceiling of $72.7 million in Q3 2023 and a floor of -$78.8 million in Q4 2025.
  • Median EBITDA over the past 5 years was $35.2 million (2023), compared with a mean of $30.3 million.
  • Biggest five-year swings in EBITDA: skyrocketed 742.38% in 2021 and later plummeted 274.63% in 2025.
  • Amphastar Pharmaceuticals' EBITDA stood at $24.3 million in 2021, then skyrocketed by 56.0% to $37.8 million in 2022, then surged by 42.68% to $54.0 million in 2023, then decreased by 16.37% to $45.1 million in 2024, then plummeted by 274.63% to -$78.8 million in 2025.
  • The last three reported values for EBITDA were -$78.8 million (Q4 2025), $25.3 million (Q3 2025), and $42.2 million (Q2 2025) per Business Quant data.